Hong Kong-based AI drug discovery company Insilico Medicine is partnering with a US-based organization to develop artificial intelligence models aimed at extending human lifespan.
Insilico Medicine, known for applying machine learning to accelerate drug discovery, is expanding its focus to longevity research through the collaboration. The partnership represents the firm's commitment to leveraging AI technology beyond traditional pharmaceutical development.
The company, operating as Insilico Medicine Cayman TopCo, has built a track record of using artificial intelligence to identify novel drug candidates and predict biological outcomes. This latest initiative channels that expertise toward understanding and potentially extending human healthspan and lifespan.
The specifics of the US partnership, including timeline and funding details, have not been disclosed. The move aligns with growing industry interest in longevity science, where AI tools are increasingly deployed to analyze complex biological data and identify interventions that could slow aging processes.
Insilico's expansion into longevity underscores how AI drug discovery platforms are diversifying applications across the biotech landscape.
Macquarie University has replaced in-person psychology classes with an AI chatbot called Virtual Peer in two mandatory units. The move reflects a broader institutional trend toward automating teaching roles.
Fambot is building an AI assistant designed to manage the administrative overhead of family life. The tool handles emails, calendars, school updates, and sports schedules.
Perplexity has launched Hybrid Compute, a feature that distributes workloads between cloud-based frontier models and local AI processors. The feature is now available to all Mac app users.
AIR has raised $50 million to provide companies with tools to discover, monitor, and control AI agents operating within their organizations. The platform continuously vets agent skills and add-ons while blocking unwanted behavior.